综述:炎症性肠病中5-氨基水杨酸的安全撤药策略
5-氨基水杨酸(5-ASA)在炎症性肠病(IBD)中广泛使用,但证据提示部分患者可安全撤药。本文综述了撤药的 rationale、UC 和 CD 中的现有证据及结直肠癌预防数据,提出基于证据的撤药策略:UC 需个体化评估,CD 患者及生物制剂升级后缓解的 UC 患者可考虑撤药。
要点
- 5-ASA 占溃疡性结肠炎总医疗费用高达25%,且近三分之一克罗恩病患者长期使用而无明确获益证据。
- 溃疡性结肠炎撤药最安全者为深度缓解且无以下风险因素:年龄<40岁、缓解<2年、多次复发史、广泛病变。
- 所有克罗恩病患者及升级至生物制剂后缓解的溃疡性结肠炎患者应考虑撤药;5-ASA 的化学预防获益成本效益比欠佳。
核心结论
- 多数IBD患者病程中接受5-ASA,但许多患者可安全撤药,对健康经济学和患者体验有重要影响,但仍存未解问题。
研究设计与样本
- 综述:检索PubMed英文文献,优先纳入随机临床试验和荟萃分析。
主要发现
- 5-ASA治疗占溃疡性结肠炎总医疗费用高达25%,近三分之一克罗恩病患者接受长期5-ASA治疗但无明确获益证据。
- 溃疡性结肠炎撤药最安全者为深度缓解且无年龄<40岁、缓解<2年、多次复发史、广泛病变等风险因素。
- 升级至生物制剂后达到缓解的溃疡性结肠炎患者及所有克罗恩病患者应考虑5-ASA撤药。
- 5-ASA对结直肠癌可能有化学预防获益,但成本效益比显著,对已缓解并接受其他药物治疗或持续缓解无广泛病变史者证据不支持该适应证。
关键数值与推荐
- 溃疡性结肠炎撤药需个体化,最安全条件:深度缓解且无年龄<40岁、缓解<2年、多次复发史、广泛病变。
- 所有克罗恩病患者可考虑5-ASA撤药。
- 升级至生物制剂并达到缓解的溃疡性结肠炎患者可考虑5-ASA撤药。
临床怎么用
- 对溃疡性结肠炎患者应个体化评估5-ASA撤药,优先考虑深度缓解且无风险因素者。
- 克罗恩病患者及生物制剂升级后缓解的溃疡性结肠炎患者可考虑停用5-ASA。
- 5-ASA用于结直肠癌化学预防需权衡成本效益,不推荐用于已缓解接受其他药物或持续缓解无广泛病变史者。
局限性
- 仅纳入英文文献,未报告具体研究数量或样本量。
- 仍存在多个未解问题,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 5-aminosalicylates (5-ASA) are widely used in inflammatory bowel disease (IBD), but emerging evidence suggests that they may be safely withdrawn in significant subsets of patients. This is important to address: 5-ASA therapy accounts for up to 25% of total healthcare costs in ulcerative colitis (UC), while almost a third of patients with Crohn's disease (CD) receive long-term 5-ASA despite no clear evidence of benefit. Further, rationalising medication burden may improve overall adherence and outcome. AIMS: To summarise the rationale for 5-ASA withdrawal, review the current evidence in both UC and CD and consider the data surrounding colorectal cancer (CRC) prevention, guiding an evidence-based withdrawal strategy. METHODS: PubMed was searched to identify relevant studies. Only papers published in English were reviewed, with priority given to randomised clinical trials and meta-analyses. RESULTS: For patients with UC, consideration of 5-ASA withdrawal should be made on a case-by-case basis, but it appears safest for those in deep remission without any of the following risk factors: younger age (<40 years), remission for less than 2 years, a history of multiple flares, extensive disease. 5-ASA withdrawal should also be considered in patients with UC escalated to biologic therapy who have achieved remission and in all patients with CD. Although 5-ASA therapy may have chemopreventive benefits for CRC, the cost-benefit ratio appears significant, and this indication is not justified by evidence in those who have achieved remission and are continuing therapy with other agents, or in those in sustained remission without a history of extensive disease. CONCLUSIONS: Although the majority of patients with IBD receive 5-ASA during their disease course, safe withdrawal appears possible in many, with important implications for both health economics and patient experience. A number of unanswered questions, however, remain.
引用
- Chapman TP, Frias Gomes C, Louis E, et al. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2020. PMID: 32452591. doi:10.1111/apt.15771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。